Tag Archives: ideas

3 Of Seeking Alpha’s Best, Part II

Summary As a hedge fund manager, who do I think is worth following on SA? 3 (more) writers I take seriously and think you should too. This is the second in a continuing series. In Part I , I looked at three of Seeking Alpha’s best contributors. In this sequel, I offer three more worth following. They all happen to be hedge fund managers and friends of mine. Whitney Tilson Whitney Tilson founded and manages Kase Capital and he wrote The Art of Value Investing and More Mortgage Meltdown . He has been a valuable contributor to Seeking Alpha, especially on the short side. I want to highlight some of his short ideas that I found most compelling at the time. He has been one of the most consistent voices on the issue of World Acceptance (NASDAQ: WRLD ) since publishing his compelling investment thesis, World Acceptance: A Battleground Stock I’m Short . One of the next up was K12 (NYSE: LRN ). Shorting can be a painful waiting game, but he did not have to wait long on An Analysis Of K12 And Why It Is My Largest Short Position . For more on LRN, he also published this slide presentation. Whitney is probably best known on Seeking Alpha for the quality (and quantity) of his devastating work on Lumber Liquidators (NYSE: LL ), starting with My Analysis Of Lumber Liquidators’ Updated Guidance . Here was my reaction to the 60 Minutes episode on LL: Whitney, Well done and congratulations! It was a terrific and compelling piece. The LL founder was evasive and deceptive. I replayed his comments several times. He knew . This is an important and favorable development for short sellers. Shorting and exposing truth is not a conflict of interest – it is a confluence of interest. Ethics involves not lying/cheating/stealing; we cannot rely on the cheap substitute of listening only to people with nothing at stake. Modern investment management has often tried to rely on both thinking substitutes and ethics substitutes. Thinking substitutes such as diversification and volatility minimizing have fared poorly but have not yet been abandoned. Ethics substitutes (“listen to me because I promise that I have at no time and in no place ever even thought about doing with my own money what I now tell you to do with yours”) have fared just as badly but are still in daily use. Your 60 Minutes segment is a big step towards real morality in business and investing. Sure, you are invested in the outcome, but you are invested because your view – and the evidence you lay out – supports that outcome. That is a bigger deal than whatever ultimately happens to LL. Finally, it serves the interest of free enterprise and free trade to have markets self-policed. Pieces such as this can protect markets from inevitable calls to have endless central planning and control. The best way to counteract the self-interest of cheaters is with the interest of short-sellers. While the government may have the resources, it never seems to have the speed to act when it counts. You have both and did something about it. Chris DeMuth Jr. InterOil (NYSE: IOC ) is one that we have both followed for a long time. I wrote about our IOC short on my blog and in InterOil Increases Production… Whitney’s thinking was helpful to the short thesis, including his article Why There’s More Downside To Come For InterOil . When he wrote The Beginning Of The End Of The 3D Printing Bubble… …it was, in fact, the beginning of the end of the 3D printing bubble. Unilife (NASDAQ: UNIS ) has been a favorite topic of mine on my blog here and here , as well as in an article on my favorite pairs trade. While I do my own work, Whitney’s contribution to the topic further solidified my thinking on this company. Ben Axler Ben Axler founded Spruce Point Capital, a long/short hedge fund. He has exposed over $1.0 billion of alleged listed frauds on NASDAQ and the NYSE. Want a great short idea? Read about Caesarstone Sdot-Yam (NASDAQ: CSTE ) in Ben’s article: Caesarstone: A Counter To The Bull Thesis On Quartz Countertops Suggests 40-75% Downside . It has declined by over 20% since publication, but remains expensive and risky. Value investors, skeptics, and debunkers should follow him here on Seeking Alpha and here on Twitter. You can also learn more about his hedge fund and other investment ideas on Spruce Point’s site . He was kind enough to join us for our last biannual ideas dinner in New York City last month where he gave us a devastating preview of what would happen to CSTE. His update is available here: Downgrading Caesarstone On Concerns About Its Capital Expenditure Accounting And Management’s History At Tefron . Andrew Walker A portfolio manager at Rangeley Capital, Andrew is a long-time friend. We have collaborated on investment ideas that we’ve posted on Seeking Alpha as far back as our early work on ALJ Regional Holdings ( OTCPK:ALJJ ), which I wrote about here . If you have an hour to learn about investing in small caps, you should listen to this interview. Additionally, I describe our work together here . Next year, we will launch our new Special Opportunities strategy that will focus on small-cap equity opportunities including special situations. Andrew has been chosen as the portfolio manager to run that new endeavor. He is exactly who I always wanted to run such a strategy. I will follow the example of Charlie Munger, who says that: Berkshire (NYSE: BRK.A ) (NYSE: BRK.B ) is run with decentralization almost to the point of abdication. While I plan to do the same at Rangeley, this requires the perfect people to manage specific businesses. Happily, I have the right people. Meanwhile, if you would like to hear more of Andrew’s investment ideas, he and I will both be speaking at an upcoming conference focusing on microcap investing. Conclusion These are the types of people I rely upon. Charlie Munger said that: The highest form that civilization can reach is a seamless web of deserved trust – not much procedure, just totally reliable people correctly trusting one another. This is what my web of deserved trust looks like. Who is in yours? Who should I add to mine? I intend to keep this series going, so please let me know if there is anyone who writes on Seeking Alpha who should be included in a future edition. I am always in search for idea candidates for Rangeley Capital as well as candidates for both new submissions and new members for Sifting the World . Editor’s Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.

IBB: Price Gouging Assertion Is Overblown

Summary Price gouging by Turing Pharmaceuticals and the subsequent comments by Hillary Clinton have exacerbated this sector decline. This price gouging incident has elicited widespread backlash, and in my opinion, rightfully so; however, this criticism has been unfairly painted across the entire sector. Attempts to heavy regulate the sector with government intervention will likely end in a futile effort in arresting drug price increases. The unprecedented secular growth streak in biotech has been more than tested as of late with the biotechnology officially in bear territory. IBB is down 25% from its 52-week high, from $400 to $295 per share during the recent market weakness, presenting a potential buying opportunity. Price gouging assertion and Hilary Clinton Recently, Turing Pharmaceuticals and its CEO Martin Shkreli garnered criticism after the company boosted the price of Daraprim from $13.50 to $750 per pill, resulting in a greater than 5,400% increase after acquiring the drug in August. This price gouging of a decades’ old drug drew fire from the general public on social media, and in particular, the presidential candidate and democratic front-runner Hillary Clinton (Figure 1). Figure 1 – Tweet by presidential candidate and democratic front runner Hillary Clinton referring to the drug price gouging This price gouging incident has elicited widespread backlash, and in my opinion, rightfully so; however, this criticism has been unfairly painted across the entire sector. It’s noteworthy to point out that democratic lawmakers have requested pricing policies and further information on pricing of drugs by Canadian drug marker Valeant Pharmaceuticals (NYSE: VRX ). Despite the public backlash and public statements by lawmakers, I believe this is a temporary headwind rooted in the public relations arena. Although the aforementioned example of Daraprim is an isolated and extreme example, at the end of the day, these companies are in business to make a profit, retain fiduciary responsibilities and return value to shareholders. Many contend that these prices are not sustainable, and the cost to the overall healthcare system is a huge financial burden. Qualitatively, this is true; however, this situation draws parallels to the housing market, education costs and social security. All of these areas of our economy are facing similar fates with unsustainable financial barriers to entry and unfunded liabilities. Attempts to heavy regulate the sector with government intervention will likely end in a futile effort in arresting drug price increases for the following terse reasons: 1) Companies spend billions of dollars in acquiring a company and/or billions of dollars and years of research and development costs to bring a given therapy to the market. 2) These costs must be reasonably factored into the pricing of the product. If government intervention is successful, this will hinder innovation and M&A activity since the back-end reward will no longer generate lucrative rewards. 3) Unlike education costs, housing price increases and social security, drug pricing is negotiated with many insurers and organizations that dispense drugs at a substantial discount to the market price and often along with rebate programs. 4) Loss of exclusivity; drug companies must also capitalize on their window of exclusivity to their drugs. Depending on patent expiration, after varying time on the market, patents will inevitably expire, and these drugs will no longer possess exclusivity and face generic competition. 5) Taken together in concert with the fact that the Affordable Care Act (ACA) is now law of the land, no one will be paying the market price of any drug since the annual deductible and maximum out-of-pocket is established depending on the tier of coverage he/she chooses. 6) Lastly, an often overlooked benefit is the cost savings to the overall healthcare system. This occurs when curative drugs or drugs that increase the overall survival and/or improve the quality of life are introduced to the market. These highly effective drugs can effectively remove patients from the system whereby eliminating years of high-cost medical treatment and hospitalization. While drug prices continue to rise, there’s substantive rational in the form of input costs, loss of exclusivity, curative treatments, increase in quality of life and removal of some patients from the overall healthcare system, thus reducing the overall cost burden of the given healthcare system. For the reasons stated above, I personally feel that these attempts by lawmakers will end in a futile endeavor. Overview The culmination of extraneous events such as sustained lower oil prices, an ostensibly imminent rate hike and weakness in China have indiscriminately plummeted the biotech sector in lock-step with the broader indices. Now, a second and more specific wave of sector-related stories such as price gouging by Turing Pharmaceuticals and the subsequent comments by Hillary Clinton has exacerbated this sector decline. These former events are ostensibly unrelated to the biotechnology sector; yet, this group has been taken along for the downhill ride with the broader indices. The latter events have been detrimental to all biotechnology stocks as this is a direct threat to pricing power and our capitalism-based structure. The unprecedented secular growth streak in biotech has been more than tested as of late with the biotechnology officially in bear territory. These latest events, some unrelated and others directly related to the biotech sector, may provide a unique opportunity to add to a current position or initiate a position over time as this correction continues to unfold. Based on annual and cumulative performance throughout both bear and bull markets, the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB ) may provide the opportunity investors have been waiting for in the face of our current market conditions. IBB is down 25% from its 52-week high, shares have plunged from $400 to $295 per share during the recent market weakness, presenting a potential buying opportunity. Debunking the bubble thesis Many content that this sector is in bubble territory based on its overall high P/E ratio, lack of adequate cash flows, and in some cases, lack of any marketable products. Thus, many companies are not deserving of this generous P/E. Many also try to draw parallels to the dot.com bubble that occurred in the early 2000s and use this as a proxy for the current biotech “bubble”. I would counter that after the most recent correction of ~25% this narrative holds much less weight and that traditional metrics on which to evaluate stocks are not applicable when evaluating clinical-stage biotech companies. Clinical-stage biotech companies are solely evaluated and priced based on potential sales of pipeline candidates and/or valuation to a potential acquirer. Holding clinical-stage biotech companies to the same standards as a traditional Dow Jones stock isn’t appropriate, and thus, I feel that this argument is flawed. Comparison to the dot.com bubble is not an accurate proxy either as the Internet companies relied heavily on user growth, subscribers, ad revenue and crowd-sourced content. This is in sharp contrast to biotech companies that innovate in the many different disease states and may have a multi-billion life-saving blockbuster drug around the corner to drastically change the trajectory of the company and its future. Additionally, major M&A activity has always been a driving factor in this sector due to the fact that companies are willing to pay very high premiums for the rights to potential blockbusters or a robust pipeline to replenish its own outdated pipeline. Taken together, I feel that after the recent sell-off and lack of any substantive argument against the biotech sector, this may be a great entry point. Perennial performer in bear and bull markets Despite the headwinds outlined above, the biotech sector has exhibited its resilience in both bear and bull markets with secular growth over the past decade. The returns for IBB have been very impressive in both annual and cumulative performance, unparalleled by any major index. Over the past 10- and 5-year time frames, IBB has posted cumulative returns of over 310% and 265%, respectively. These results are unrivaled by any major index, outperforming on a 10-year cumulative basis by 3-fold or greater when compared to the S&P 500, NASDAQ, and Dow Jones (Figure 2). These returns are accentuated during the previous 5 years. IBB notched cumulative returns of 265%, outperforming the S&P 500, NASDAQ and Dow Jones by roughly 2.5-fold or greater over this 5-year time frame (Figure 3). (click to enlarge) Figure 2 – Google Finance; comparison of IBB returns relative to the S&P 500, NASDAQ, Dow Jones over the previous 10 years (click to enlarge) Figure 3 – Google Finance; comparison of IBB returns relative to the S&P 500, NASDAQ, Dow Jones over the previous 5 years IBB has displayed impressive resilience in the face of the market crash in 2008, the bear markets of 2011 and the choppy market thus far in 2015. During the market crash of 2008, IBB posted an annual return of -12.2% while the S&P 500, NASDAQ and Dow Jones posted returns of -37.0%, -40.0% and -31.9%, respectively (Figure 3). During the bear market of 2011, IBB posted an annual return of 11.7% while the S&P 500, NASDAQ and Dow Jones posted returns of 2.1%, -0.8% and 8.4%, respectively (Figure 4). Thus far, during the choppy market of 2015, IBB posted an annual return of 4% while the S&P 500, NASDAQ and Dow Jones posted returns of -6.3%, -1.4% and -8.6%, respectively (Figure 5). These data suggest that IBB outperforms during bear markets as well as bull markets to establish itself as a secular growth sector. (click to enlarge) Figure 4 – Morningstar comparison of IBB’s annual returns relative to the NASDAQ over the previous 10 years (click to enlarge) Figure 5 – Google Finance; comparison of IBB’s annual performance thus far in 2015 relative to the S&P 500, NASDAQ and Dow Jones Conclusion As the confluence of broader disconnected factors and price gouging inquiries by leading politicians continue to bring down the biotechnology sector, it may be time to consider capitalizing on this correction via adding to existing positions or initiating a new position in this cohort given this opportunity. As the United States continues to absorb an ageing population alongside growing overall healthcare costs, more specifically prescription drug costs, the biotech sector looks poised to benefit and continue to outperform the broader market. Data suggests, provided a long-term position that volatility within the biotech sector is negated by its long-term performance that is unparalleled by any major index. This sector provides high returns unrivaled by any major index with moderate risk (based on its resilience during the bear markets of 2008 and 2011 and thus far in 2015) and volatility. IBB may be providing investors with a great opportunity to add or initiate a position for any long portfolio desiring exposure to the biotechnology sector with a long-term time horizon given the recent market conditions. Disclosure The author currently holds shares of IBB and is long IBB. The author has no business relationship with any companies mentioned in this article. I am not a professional financial advisor or tax professional. I wrote this article myself and it reflects my own thoughts and opinions. This article is not intended to be a recommendation to buy or sell any stock or ETF mentioned. I am an individual investor who analyzes investment strategies and disseminates my analyses. I encourage all investors to conduct their own research and due diligence prior to investing. Please feel free to comment and provide feedback, I value all responses.

No Imminent Lift Off? Time For These Dividend ETFs

Dividend investing has seen a lukewarm year so far in the U.S. as the markets speculated a faster-than-expected Fed lift-off prompted by steady growth in the domestic economy. As a result, most dividend ETFs are trading in red in the year-to-date frame. However, a volatile start to Q4 has once again put the spotlight on income-focused investing. Moreover, a still-patient Fed and the likelihood of more cheap money inflows cheered up dividend investing all over again. Be it bonds, high dividend equities, or pass-through securities, picks that target higher yielding securities have fared well since the dovish September Fed meet. The allure rose further after the U.S. economy reported sub-par job data for the month of September last week. The soft jobs’ report has raised questions over the health of the U.S. economy and the fate of Fed’s policy tightening. Headline job gains for September came in at 142K versus the estimated 200K and the prior month’s tally of 136K (read: ETFs that Gained & Lost Post Dismal Job Data ). The originally reported July tally was also revised lower to 223K from 245K originally. The year-to-date monthly pace of job gains now averages 198K, though the pace for the last three months was way lower at 167K. This goes against the monthly average of 260K for 2014. While a subdued inflation data and global growth worries were already obstacles on the course of the Fed policy, the job data made the case worse and Fed’s policy tightening seems some way off. Investors who were earlier overconfident about a December rate hike in the U.S., have now started to push back the timeline to early next year, presuming a sluggish U.S. economic rebound. While it is a decent setting for capital gains, Treasury bond yields slumped and are at 2.07% at the time of writing, leading some to believe that a new bull market may be at hand. In this type of an environment, investors can count on income picks for Q4. While individual stock pick is always an option, ETFs give options to fairly diversify one’s portfolio. 4 Dividend ETF Picks for Q4 SPDR S&P International Dividend ETF (NYSEARCA: DWX ) If you want to stay global, DWX could be your ticket as this fund focuses only on high yielding stocks from around the globe. After all, most developed economies are supposed to carry on their accommodative stance next year unlike the U.S. This is done by tracking the S&P International Dividend Opportunities Index, a benchmark that holds about 100 securities in its basket. Currently, the $1 billion-fund is a bit heavy on traditional high yield sectors like financials (24.8%), utilities (22.8%), telecom (15.9%), and energy (14.2%), though no single company accounts for more than 3.4% of the total assets. In terms of yields, this pays a solid 5.91%, while it charges investors a reasonable 45 basis points a year in fees for the service. The fund was up over 6.9% in the last five days (as of October 5, 2015). Vanguard High Dividend Yield ETF (NYSEARCA: VYM ) This large cap centric fund provides exposure to the high yielding U.S. dividend stocks by tracking the FTSE High Dividend Yield Index and could thus be a lucrative option for those seeking higher current income. The ETF is one of the largest and popular choices in the dividend ETF space with AUM of over $10.3 billion. Expense ratio comes in at 10 bps (read: 3 Excellent Dividend ETFs for Growth and Income ). In terms of sector, the fund is widely spread out with financials, consumer goods, technology, industrials, health care, and oil & gas taking double-digit exposure in the basket. The fund yields 3.33% as of October 5 and was up over 5.6% in the last five trading sessions. The ETF has a Zacks ETF Rank #3 (Hold) with a Medium risk outlook (read: 3 Cheap Value ETFs with Strong Dividend ). Schwab U.S. Dividend Equity ETF (NYSEARCA: SCHD ) This fund tracks the Dow Jones U.S. Dividend 100 Index, which measures the performance of high dividend yielding U.S. stocks that have a record of consistently paying dividends. Notably, companies, that raise dividends regularly, appear steadier than those which offer higher yields. In a market crash, these dividend aristocrats stand out pretty strong and navigate through volatility. The product has already amassed roughly $2.51 billion in assets and has a dividend yield of 3.15%. The fund charges a meager 7 bps in fees and trades in solid volume of more than 500,000 shares per day. Consumer Staples is the fund’s focus sector with about one-fourth exposure followed by IT (19.74%) and Industrials (13.85%). It currently has a Zacks Rank #3 and added about 5.3% in the last five trading sessions (as of October 5, 2015). SPDR Dividend ETF (NYSEARCA: SDY ) This fund provides exposure to the 102 U.S. stocks that have been consistently increasing their dividend every year for at least 25 years. It follows the S&P High Yield Dividend Aristocrats Index and has amassed $12 billion in AUM. Volume is solid, exchanging more than 765,000 shares in hand, while expense ratio comes in at 0.35%. The product is widely diversified across components as each security accounts for less than 2.81% of total assets. Financials is the top sector taking up one-fourth of the portfolio while consumer staples (15.1%), industrials (13.4%) and utilities (11.8%) round off the next three spots. The fund was up nearly 5% in the last five days and has a Zacks ETF Rank of 3. Link to the original post on Zacks.com